Anemia on Chronic Kidney Disease: The Role of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors

Anemia is one of the homeostatic abnormalities caused by chronic kidney disease and also frequently problem encountered in end-stage renal patients, regardless hemodialysis treatment. significantly impairs function, increases morbidity mortality risk, deteriorates quality life. Chronic disease’s patients with anemia conditions are affected numerous factors, including decreased production endogenous erythropoietin, functional absolute iron deficiency, elevated hepcidin levels due to inflammation, particularly patients. Treatment options for include exogenous erythropoietin supplementation. A new mechanism known as "hypoxia-sensing system" termed a mediator synthesis, has been proposed boost synthesis. The hypoxia-inducible factor activates specific gene expression contributes physiological response lower tissue oxygen levels. who contraindicated or hyporesponsive therapy erythropoiesis-stimulating drugs may utilize this an alternative.